Wells Fargo & Company Context Therapeutics Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 116 shares of CNTX stock, worth $211. This represents 0.0% of its overall portfolio holdings.
Number of Shares
116
Previous 114
1.75%
Holding current value
$211
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CNTX
# of Institutions
27Shares Held
4.12MCall Options Held
0Put Options Held
0-
Opaleye Management Inc. Boston, MA1.11MShares$2.02 Million0.37% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY726KShares$1.32 Million0.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA598KShares$1.09 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY329KShares$598,4460.07% of portfolio
-
Ubs Oconnor LLC Chicago, IL297KShares$539,9480.03% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $29.1M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...